Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedEC
Euclidean Capital
Activity from announced rounds
Activity in this selectionxyz-venture-capital-d246227f
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $107M 2 disclosed · full round size, not this investor’s share